Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jun 15;5(8):1218-1221.
doi: 10.1002/ccr3.1040. eCollection 2017 Aug.

Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the -1774delG polymorphism in the Abcc2 gene

Caroline C B Braga  1 , Bruno Deltreggia Benites  1 , Dulcineia M de Albuquerque  1 , Marisa C Alvarez  1 , Tiago Seva-Pereira  2 , Bruno K L Duarte  1 , Fernando F Costa  1 , Simone C O Gilli  1 , Sara T O Saad  1
Affiliations
Case Reports

Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the -1774delG polymorphism in the Abcc2 gene

Caroline C B Braga et al. Clin Case Rep. .

Abstract

This manuscript describes the case of a patient with sickle cell anemia who died of fulminant hepatitis after therapy with the iron chelator Deferasirox. The patient was homozygous for the -1774delG polymorphism in the Abcc2 gene, which raises the concern about the use of hepatotoxic drugs in this specific context.

Keywords: Abcc2; Deferasirox; liver failure; polymorphisms; sickle cell disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Laboratory parameters and their evolution over the period of patient evaluation. (A) AST, ALT, Alkaline Phosphatase; (B) INR; (C) HbS in %.
See this image and copyright information in PMC

References

    1. Cherry, M. G. , Greenhalgh J., Osipenko L., Venkatachalam M., Boland A., Dundar Y., et al. 2012. The clinical effectiveness and cost‐effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation. Health Technol. Assess. 16:1–129. - PMC - PubMed
    1. Mousa, A. S. , Al Momem A., Al Sayegh F., Al Jaouni S., Nasrullah Z., Al Saeed H., et al. 2010. Review: management of painful Vaso‐occlusive crisis of sickle‐cell anemia: consensus opinion. Clin. Appl. Thromb. 16:365–376. - PubMed
    1. Vichinsky, E. P. , and Ohene‐Frempong K.; Transfusion Committee. 2011. Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey. Pediatr. Hematol. Oncol. 28:37–42. - PubMed
    1. Cappellini, M. D. , Porter J., El‐Beshlawy A., Li C. K., Seymour J. F., Elalfy M., et al. 2010. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion‐dependent anemias. Haematologica 95:557–566. - PMC - PubMed
    1. Kontoghiorghes, G. J. 2007. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin. Drug Saf. 6:235–239. - PubMed

Publication types

LinkOut - more resources